Lithospermic acid B ameliorates the development of diabetic nephropathy in OLETF rats

Eun Seok Kang; Geun Taek Lee; Beom Seok Kim; Chul Hoon Kim; Gi Ho Seo; Seung Jin Han; Kyu Yeon Hur; Chul Woo Ahn; Hunjoo Ha; Mankil Jung; Young Soo Ahn; Bong Soo Cha; Hyun Chul Lee

doi:10.1016/j.ejphar.2007.10.070

Lithospermic acid B ameliorates the development of diabetic nephropathy in OLETF rats

Eun Seok Kang
, Geun Taek Lee
, Beom Seok Kim
, Chul Hoon Kim
, Gi Ho Seo
, Seung Jin Han
, Kyu Yeon Hur
, Chul Woo Ahn
, Hunjoo Ha
, Mankil Jung
, Young Soo Ahn
, Bong Soo Cha
, Hyun Chul Lee

Department of Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

43 Scopus citations

Abstract

Lithospermic acid B (LAB), an active component isolated from Salvia miltiorrhizae, has been reported to have renoprotective effects in type 1 diabetic animal models. In the present study we investigated the effects of LAB on the prevention of diabetic nephropathy in type 2 diabetic Otsuka Long-Evans-Tokushima Fatty (OLETF) rats. LAB (20 mg/kg) was given orally once daily to 10-week-old male OLETF rats for 28 weeks. Treatment of OLETF rats with LAB had little effects on body weight and blood glucose levels. Treatment with LAB resulted in significant reduction in blood pressure. LAB markedly attenuated albuminuria and significantly lowered levels of lipid peroxidation, monocyte chemoattractant protein-1 (MCP-1), and transforming growth factor-β (TGF-β1) expression in renal tissues of OLETF rats. In addition, LAB inhibited the progression of glomerular hypertrophy, mesangial expansion, and expansion of the extracellular matrix in the renal cortex. Collectively, these results suggest that LAB has beneficial effects on the diabetic nephropathy in OLETF rats by decreasing blood pressure, oxidative stress, and MCP-1 expression. Our results suggest that LAB might be a new therapeutic agent for the prevention of nephropathy in type 2 diabetes.

Original language	English
Pages (from-to)	418-425
Number of pages	8
Journal	European Journal of Pharmacology
Volume	579
Issue number	1-3
DOIs	https://doi.org/10.1016/j.ejphar.2007.10.070
State	Published - 28 Jan 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Diabetic nephropathy
Lithospermate B
MCP-1
OLETF rats
Oxidative stress
Type 2 diabetes

Access to Document

10.1016/j.ejphar.2007.10.070

Cite this

@article{fb49caf57d5f4a0c88adefcc3b5b3ce0,

title = "Lithospermic acid B ameliorates the development of diabetic nephropathy in OLETF rats",

abstract = "Lithospermic acid B (LAB), an active component isolated from Salvia miltiorrhizae, has been reported to have renoprotective effects in type 1 diabetic animal models. In the present study we investigated the effects of LAB on the prevention of diabetic nephropathy in type 2 diabetic Otsuka Long-Evans-Tokushima Fatty (OLETF) rats. LAB (20 mg/kg) was given orally once daily to 10-week-old male OLETF rats for 28 weeks. Treatment of OLETF rats with LAB had little effects on body weight and blood glucose levels. Treatment with LAB resulted in significant reduction in blood pressure. LAB markedly attenuated albuminuria and significantly lowered levels of lipid peroxidation, monocyte chemoattractant protein-1 (MCP-1), and transforming growth factor-β (TGF-β1) expression in renal tissues of OLETF rats. In addition, LAB inhibited the progression of glomerular hypertrophy, mesangial expansion, and expansion of the extracellular matrix in the renal cortex. Collectively, these results suggest that LAB has beneficial effects on the diabetic nephropathy in OLETF rats by decreasing blood pressure, oxidative stress, and MCP-1 expression. Our results suggest that LAB might be a new therapeutic agent for the prevention of nephropathy in type 2 diabetes.",

keywords = "Diabetic nephropathy, Lithospermate B, MCP-1, OLETF rats, Oxidative stress, Type 2 diabetes",

author = "Kang, \{Eun Seok\} and Lee, \{Geun Taek\} and Kim, \{Beom Seok\} and Kim, \{Chul Hoon\} and Seo, \{Gi Ho\} and Han, \{Seung Jin\} and Hur, \{Kyu Yeon\} and Ahn, \{Chul Woo\} and Hunjoo Ha and Mankil Jung and Ahn, \{Young Soo\} and Cha, \{Bong Soo\} and Lee, \{Hyun Chul\}",

year = "2008",

month = jan,

day = "28",

doi = "10.1016/j.ejphar.2007.10.070",

language = "English",

volume = "579",

pages = "418--425",

journal = "European Journal of Pharmacology",

issn = "0014-2999",

publisher = "Elsevier B.V.",

number = "1-3",

}

TY - JOUR

T1 - Lithospermic acid B ameliorates the development of diabetic nephropathy in OLETF rats

AU - Kang, Eun Seok

AU - Lee, Geun Taek

AU - Kim, Beom Seok

AU - Kim, Chul Hoon

AU - Seo, Gi Ho

AU - Han, Seung Jin

AU - Hur, Kyu Yeon

AU - Ahn, Chul Woo

AU - Ha, Hunjoo

AU - Jung, Mankil

AU - Ahn, Young Soo

AU - Cha, Bong Soo

AU - Lee, Hyun Chul

PY - 2008/1/28

Y1 - 2008/1/28

N2 - Lithospermic acid B (LAB), an active component isolated from Salvia miltiorrhizae, has been reported to have renoprotective effects in type 1 diabetic animal models. In the present study we investigated the effects of LAB on the prevention of diabetic nephropathy in type 2 diabetic Otsuka Long-Evans-Tokushima Fatty (OLETF) rats. LAB (20 mg/kg) was given orally once daily to 10-week-old male OLETF rats for 28 weeks. Treatment of OLETF rats with LAB had little effects on body weight and blood glucose levels. Treatment with LAB resulted in significant reduction in blood pressure. LAB markedly attenuated albuminuria and significantly lowered levels of lipid peroxidation, monocyte chemoattractant protein-1 (MCP-1), and transforming growth factor-β (TGF-β1) expression in renal tissues of OLETF rats. In addition, LAB inhibited the progression of glomerular hypertrophy, mesangial expansion, and expansion of the extracellular matrix in the renal cortex. Collectively, these results suggest that LAB has beneficial effects on the diabetic nephropathy in OLETF rats by decreasing blood pressure, oxidative stress, and MCP-1 expression. Our results suggest that LAB might be a new therapeutic agent for the prevention of nephropathy in type 2 diabetes.

AB - Lithospermic acid B (LAB), an active component isolated from Salvia miltiorrhizae, has been reported to have renoprotective effects in type 1 diabetic animal models. In the present study we investigated the effects of LAB on the prevention of diabetic nephropathy in type 2 diabetic Otsuka Long-Evans-Tokushima Fatty (OLETF) rats. LAB (20 mg/kg) was given orally once daily to 10-week-old male OLETF rats for 28 weeks. Treatment of OLETF rats with LAB had little effects on body weight and blood glucose levels. Treatment with LAB resulted in significant reduction in blood pressure. LAB markedly attenuated albuminuria and significantly lowered levels of lipid peroxidation, monocyte chemoattractant protein-1 (MCP-1), and transforming growth factor-β (TGF-β1) expression in renal tissues of OLETF rats. In addition, LAB inhibited the progression of glomerular hypertrophy, mesangial expansion, and expansion of the extracellular matrix in the renal cortex. Collectively, these results suggest that LAB has beneficial effects on the diabetic nephropathy in OLETF rats by decreasing blood pressure, oxidative stress, and MCP-1 expression. Our results suggest that LAB might be a new therapeutic agent for the prevention of nephropathy in type 2 diabetes.

KW - Diabetic nephropathy

KW - Lithospermate B

KW - MCP-1

KW - OLETF rats

KW - Oxidative stress

KW - Type 2 diabetes

UR - https://www.scopus.com/pages/publications/37549006055

U2 - 10.1016/j.ejphar.2007.10.070

DO - 10.1016/j.ejphar.2007.10.070

M3 - Article

C2 - 18031723

AN - SCOPUS:37549006055

SN - 0014-2999

VL - 579

SP - 418

EP - 425

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

IS - 1-3

ER -

Lithospermic acid B ameliorates the development of diabetic nephropathy in OLETF rats

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this